A Study of TAK-861 in People With Narcolepsy Type 1
- Registration Number
- NCT06505031
- Lead Sponsor
- Takeda
- Brief Summary
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.
- Detailed Description
The drug being tested in this study is called TAK-861. TAK-861 is being tested to evaluate its efficacy and safety in participants with narcolepsy with cataplexy (narcolepsy type 1 \[NT1\]).
The study will enroll approximately 93 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
1. TAK-861
2. Placebo
The study drug will be administered for 12 weeks. This multi-center trial will be conducted globally.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 105
- The participant has a body mass index (BMI) within the range 18 to 40 kilograms per meter square (kg/m^2).
- The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1.
- The participant has greater than or equal to (≥)4 partial or complete episodes of cataplexy/week (WCR).
- The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant's cerebrospinal fluid (CSF) orexin (OX)/hypocretin-1 concentration is less than or equal to (≤)110 picograms per milliliter (pg/mL) [or less than one-third of the mean values obtained in normal participants within the same standardized assay].
- The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
- The participant: (a) has a history of myocardial infarction; (b) has a history of clinically significant hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or (c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease).
- The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
- The participant has a history of cancer in the past 5 years.
- The participant has a clinically significant history of head injury or head trauma.
- The participant has a history of epilepsy, seizure, or convulsion.
- The participant has any current unstable psychiatric disorder or current active major depressive episode (MDE) or an active MDE in the past 6 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TAK-861 TAK-861 Participants will receive TAK-861 tablets, orally, for 12 weeks. Placebo Placebo Participants will receive TAK-861-matching placebo tablets, orally, for 12 weeks.
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials Baseline, Week 12 The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session will be recorded. Participants will be required to stay awake in between the 4 sessions.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 12 in ESS Total Score Baseline, Week 12 The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.
Weekly Cataplexy Rate (WCR) at Week 12 Week 12 Change From Baseline to Week 12 in Mean Number of Lapses on the 3 Psychomotor Vigilance Test (PVT) Baseline, Week 12 The PVT is a simple reaction performance task that aims to measure sustained attention. The change from baseline in the mean number of lapses (delayed responses to a visual cue from intraday sessions) during the 10 minute test will be used as a measure of objective sustained attention.
Patient Global Impression of Change (PGI-C) Score at Week 12 Week 12 The PGI-C is a patient self-rated scale to assess improvement in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score Baseline, Week 12 The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome.
Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores Baseline, Week 12 The FINI measures the functional impacts of narcolepsy across 6 domains. Each domain is scored from 0 to 4, where 0 indicates the best health and 4 the worst.
Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores Baseline, Week 12 The SF-36 is participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. The scores for each component range from 0 to 100. Higher scores represent better health-related quality of life.
Number of Participants with At Least one Treatment-Emergent Adverse Event (TEAE) Up to 16 weeks An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
Trial Locations
- Locations (28)
Takeda Site 22
🇦🇹Linz, Austria
Takeda Site 25
🇧🇪Ghent, Belgium
Takeda Site 24
🇧🇪Leuven, Belgium
Takeda Site 23
🇧🇪Liege, Belgium
Takeda Site 27
🇨🇳Zhengzhou, Henan, China
Takeda Site 28
🇨🇳Shanghai, Shanghai, China
Takeda Site 26
🇨🇳Guangdong, China
Takeda Site 20
🇫🇮Helsinki, Finland
Takeda Site 21
🇫🇮Tampere, Finland
Takeda Site 16
🇫🇷Leon, Bordeaux, France
Takeda Site 14
🇫🇷Marseille, France
Takeda Site 15
🇫🇷Nantes, France
Takeda Site 17
🇮🇹Pozzilli, Italy
28003
🇪🇸Barcelona, Spain
Takeda Site 19
🇸🇪Uppsala, Sweden
Takeda Site 1
🇦🇺Glebe, New South Wales, Australia
Takeda Site 2
🇧🇪Alken, Belgium
Takeda Site 3
🇧🇪Erpent, Belgium
Takeda Site 4
🇨🇳Beijing, Beijing, China
Takeda Site 6
🇫🇷Bron, France
Takeda Site 5
🇫🇷Montpellier, France
Takeda Site 7
🇮🇹Bologna, Italy
Takeda Site 8
🇮🇹Roma, Italy
Takeda Site 11
🇰🇷Seoul, Daegu, Korea, Republic of
Takeda Site 10
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
Takeda Site 12
🇰🇷Seoul, Korea, Republic of
Takeda Site 9
🇵🇱Krakow, Poland
Takeda Site 13
🇪🇸Madrid, Spain